
The Role of TLR2 in the Pathogenesis of Atherosclerosis

Sungha Park

Division of Cardiology Yonsei Cardiovascular Hospital Yonsei University Health System

What are Toll-like receptors?



Trends in Pharmacological Sciences November 2013, Vol. 34, No. 11

Circulation





Toll-Like Receptor-2 Mediates Inflammation and Matrix Degradation in Human Atherosclerosis

Claudia Monaco, MD, PhD, FESC; Scott M. Gregan, BSc; Tina J. Navin, BSc; Brian M.J. Foxwell, PhD, DSc, FRCPath[†]; Alun H. Davies, MA, BM, BCh, DM, FRCS, FHEA; Marc Feldmann, MB, BS, BSc, PhD, FRCPath, FRCP, FMedSci, FAA, FRS

TLR-2 and -4 blockade reduces NF-κB activity in human atherosclerosis








Circulation 2009;120:2462-2469

JCI The Journal of Clinical Investigation

Modulation of atherosclerosis in mice by Toll-like receptor 2

Adam E. Mullick, Peter S. Tobias, and Linda K. Curtiss

Department of Immunology, The Scripps Research Institute, La Jolla, California, USA.



J. Clin. Invest. 115:3149-3156 (2005).

The Journal of Clinical Investigation

Modulation of atherosclerosis in mice by Toll-like receptor 2

Adam E. Mullick, Peter S. Tobias, and Linda K. Curtiss

Department of Immunology, The Scripps Research Institute, La Jolla, California, USA.

- TLR2 KO results in attenuation of atherosclerosis in LDL receptor KO mice
- No difference in atherosclerotic plaque area in LDL receptor KO mice with or without BM transfer of TLR2 positive cells
- → importance of TLR2 in the vessel itself
- \rightarrow endothelium or VSMC




Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events

Adam E. Mullick,¹ Katrin Soldau,¹ William B. Kiosses,² Thomas A. Bell III,¹ Peter S. Tobias,¹ and Linda K. Curtiss¹

¹Department of Immunology and ²Core Microscopy Facility, The Scripps Research Institute, La Jolla, CA 92037

Chow-fed LDLr^{/-} mice

4-wk HFD-fed *LDLr^{/-}* mice




Endothelial cell TLR2 expression in the modulation of key atherogenic events during early lesion development

Bright Red: CD31 (endothelial cells) Green: TLR2

JEM 2008;205(2):373-383

Endothelial cell-specific TLR2 Tg mouse



YUHS data

Atherosclerosis and Vascular Smooth Muscle Cells

Vascular Smooth Muscle Cells in Atherosclerosis

Martin R. Bennett, Sanjay Sinha, Gary K. Owens

<u>Abstract:</u> The historical view of vascular smooth muscle cells (VSMCs) in atherosclerosis is that aberrant proliferation of VSMCs promotes plaque formation, but that VSMCs in advanced plaques are entirely beneficial, for example preventing rupture of the fibrous cap. However, this view has been based on ideas that there is a homogenous population of VSMCs within the plaque, that can be identified separate from other plaque cells (particularly macrophages) using standard VSMC and macrophage immunohistochemical markers. More recent genetic lineage tracing studies have shown that VSMC phenotypic switching results in less-differentiated forms that lack VSMC markers including macrophage-like cells, and this switching directly promotes atherosclerosis.

In addition, VSMC proliferation may be beneficial throughout atheroge whereas VSMC apoptosis, cell senescence, and VSMC-derived macropha We review the effect of embryological origin on VSMC behavior in a consequences of phenotypic switching, the evidence for different origin processes that VSMCs undergo in atherosclerosis in regard to plaque fo lesions. We think there is now compelling evidence that a full understandi is critical to identify therapeutic targets to both prevent and treat ather DOI: 10.1161/CIRCRESAHA.115.306361.)

Key Words: atherosclerosis ■ extracellular matrix ■ interleukin ■ platelet-



Cardiovascular Research (2014) **103**, 452–460 doi:10.1093/cvr/cvu171 REVIEW

Emerging regulators of vascular smooth muscle cell function in the development and progression of atherosclerosis

Jason Lee Johnson*

Laboratory of Cardiovascular Pathology, School of Clinical Sciences, University of Bristol, Research Floor Level Seven, Bristol Royal Infirmary, Bristol BS2 8HW, UK

Received 13 January 2014; revised 1 July 2014; accepted 14 July 2014; online publish-ahead-of-print 22 July 2014


After a period of relative senescence in the field of vascular smooth muscle cell (VSMC) research with particular regards to atherosclerosis, the last few years has witnessed a resurgence, with extensive research re-assessing potential molecular mechanisms and pathways that modulate VSMC behaviour within the atherosclerotic-prone vessel wall and the atherosclerotic plaque itself. Attention has focussed on the pathological contribution of VSMC in plaque calcification; systemic and local mediators such as inflammatory molecules and lipoproteins; autocrine and paracrine regulators which affect cell-cell and cell to matrix contacts alongside cytoskeletal changes. In this brief focused review, recent insights that have been gained into how a myriad of recently identified factors can influence the pathological behaviour of VSMC and their subsequent contribution to atherosclerotic plaque development and progression has been discussed. An overriding theme is the mechanisms involved in the alterations of VSMC function during atherosclerosis.

Keywords

Atherosclerosis • Vascular smooth muscle cells • Migration • Foam cell formation • Calcification • Matrix metalloproteinases

Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading

James X. Rong, Mark Shapiro*, Eugene Trogan*, and Edward A. Fisher[†]



VSMC in advanced plaques

- > 80% of VSMC derived cells from the plaques of Apo E KO mice lacked common SMC markers such as ACTA2
- > 30% of VSMCS in plaques express macrophge markers such as CD 68, CD11b, F4/80, Mac2
- 40% of foam cells are VSMC derived cells, expressing both SMC(ACTA2) and macrophage markers(CD68)

Circ Res 2016;118:692-702

JOURNAL OF THE AMERICAN HEART ASSOCIATION

Arteriosclerosis.


Thrombosis, and Vascular Biology


Cholesterol Loading Reprograms the MicroRNA-143/145– Myocardin Axis to Convert Aortic Smooth Muscle Cells to a Dysfunctional Macrophage-Like Phenotype

American Heart

Yuliya Vengrenyuk,* Hitoo Nishi,* Xiaochun Long, Mireille Ouimet, Nazir Savji, Fernando O. Martinez, Courtney P. Cassella, Kathryn J. Moore, Stephen A. Ramsey, Joseph M. Miano, Edward A. Fisher

Cholesterol loading of vascular smooth muscle cell (VSMC) leads to foam cell formation, loss of VSMC characteristics, and emergence of macrophage-like features.






Roles of miR-143/145 in VSMC Phenotypic Changes in Response to Cholesterol Loading

Arteriosclerosis, Thrombosis, and Vascular Biology. 2015;35:535-546

Atherosclerosis and VSMC phenotypic switching




Circ Res 2016;118:692-702

TLR2 and vascular smooth muscle cells

Does activation of TLR 2 in the VSMC mediates the development and progression of atherosclerosis?

If so, what is the possible mechanism?




TLR2 and Vascular Smooth Muscle cells


Hypothesis


- Conditional overexpression of TLR2 in VSMC will result in acceleration of atherosclerosis in Apo E KO mice
- TLR2 is important in mediating the phenotypic switch of VSMC into foam cell like cells


혈관특이적 TLR2 과발현 동맥경화 유전자변형 마우스 제작



SMC-specific TLR2 Tg mouse









Immunohistochemical staining for TLR2

SMC-specific TLR2 Tg mouse: Atherosclerosis




SMC-specific TLR2 Tg mouse: Atherosclerosis




Aortic sinus, Oil-red O staining

TLR2: Phenotypic switching of VSMC




Phenotypic switching of VSMC





TLR2: Phenotypic switching of VSMC

Effect of TLR2 on cholesterol-induced phenotypic switching of VSMC




TLR2: Phenotypic switching of VSMC in vivo






Aorta-VSMC

TLR2: Phenotypic switching of VSMC




VSMC foam cell




TLR2: VSMC foam cell

Effect of TLR2 on VSMC foam cell formation




TLR2: Inflammation of VSMC


Effect of TLR2 on cholesterol-induced VCAM expression of VSMC



TLR2: Inflammation of VSMC in vivo








Immunohistochemical staining for VCAM

Summary



- Conditional overexpression of TLR2 in VSMC results in acceleration of atherosclerosis of ApoE KO mice
- TLR2 is important in mediating the phenotypic switch of VSMC into macophage-like cells

Further study

 What is the mechanism for the entry of cholesterol into the SMCs? → mediated through CD 36, SR-A, SR-B, Lox-1, CD 68 or TLR2 itself?

 Microarray of the isolated SMCs to determine signaling mechanism associated with TLR2 mediated phenotypic switch

Acknowledgments





Han-woong Lee, PhD


Department of Biochemistry, College of Life Science & Biotechnology Yonsei Laboratory Animal Research Center Yonsei University SIRIC, Yonsei University College of Medicine

MiRan Seo, PhD Soyeon Lim, PhD Myungeun Lee, PhD Juyeon Lim Soyoung Cho Jisu Jeong Jiye Lee Minbum Kim Soyoung An Jiyeon Ko


Thank you very much for your attention




4-wk HFD-fed *LDLr^{/-}* mice











JEM 2008;205(2):373-383

Pathogenesis of Atherosclerosis




- Endothelial injury (endothelial dysfunction)
- Adherence of monocyte to endothelial cells
- Uptake of oxLDL by macrophage scavenger receptor
- Foam cell transformation: accumulation of excess lipid inside the cells
- Recruitment of VSMC (VSMC phenotype switching)
- Atherosclerotic plaque formation


혈관특이적 TLR2 과발현 동맥경화 유전자변형 마우스 제작



VSMC, oxLDL-induced foam cell formation



Int J Biol Sci. 2011;7(7):937-46.



Cell Death Dis. 2014 Apr 17;5:e1182.

Alarmins

Exogenous danger signals from microorganisms: Pathogen associated molecular patterns(Flagellin, LPS)

Endogenous danger signals from tissue damage: Damage associated molecular patterns → HMGB1,S100A12

Toll like receptor

Receptor for AGE(RAGE)

Pisetsky DS et al Arthritis Res Ther 2008;10:209